Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib

被引：0
|
作者：
Puri, S. [1 ]
Hicks, J. [2 ]
Knepper, T. [3 ]
Smith, M. [4 ]
Boyle, T. [5 ]
Gray, J. [6 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Hematol & Oncol, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Debartolo Family Personalized Med Inst, Div Populat Sci, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Debartolo Family Personalized Med Program, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program Adm, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
T790M; osimertinib; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 12.05
引用
收藏
页码：S1848 / S1849
页数：2
相关论文
共 50 条
  • [1] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [2] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [3] Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
    Chalmers, Anna
    Jensen, Leif
    Akerley, Wallace
    LUNG CANCER, 2017, 114 : 68 - 69
  • [4] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
    Arulananda, Surein
    Do, Hongdo
    Musafer, Ashan
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1728 - 1732
  • [5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [6] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [7] Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
    Alexeyenko, Andrey
    Brustugun, Odd Terje
    Eide, Inger Johanne Zwicky
    Gencheva, Radosveta
    Kosibaty, Zeinab
    Lai, Yi
    de Petris, Luigi
    Tsakonas, Georgios
    Grundberg, Oscar
    Franzen, Bo
    Viktorsson, Kristina
    Lewensohn, Rolf
    Hydbring, Per
    Ekman, Simon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (10) : 2064 - +
  • [8] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Sha Liu
    Tao Pan
    Ming-Kun Wang
    Jie Wang
    Shuang Zhang
    Ping Zhou
    Clinical Drug Investigation, 2022, 42 : 459 - 464
  • [9] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [10] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Liu, Sha
    Pan, Tao
    Wang, Ming-Kun
    Wang, Jie
    Zhang, Shuang
    Zhou, Ping
    CLINICAL DRUG INVESTIGATION, 2022, 42 (05) : 459 - 464
12345